Dr. Manyak is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Connect with other colleagues in the same hospital or clinic
- Search all U.S. specialist profiles and refer a patient
- Read the latest clinical news and earn CME/CEU credits
Office
2322 Blaine Dr
Chevy Chase, MD 20815Phone+1 301-588-1881- Is this information wrong?
Education & Training
- George Washington UniversityResidency, Urology, 1982 - 1985
- New York-Presbyterian/QueensInternship, Transitional Year, 1981 - 1982
- University of the East College of MedicineClass of 1979
Certifications & Licensure
- DC State Medical License 1982 - 2024
- PA State Medical License 2021 - 2024
- WV State Medical License 2021 - 2023
- NJ State Medical License 1981 - 2023
- DE State Medical License 2022 - 2023
- OH State Medical License 2021 - 2023
Awards, Honors, & Recognition
- Whos Who in Medicine and Healthcare Marquis Whos Who
- Fellow (FACS) American College of Surgeons
Publications & Presentations
PubMed
- NRX-101 (D-Cycloserine + Lurasidone) Is Active against Drug-Resistant Urinary Pathogens In Vitro.Michael T Sapko, Riccardo Panicucci, Jonathan C Javitt, Michael Manyak> ;Antibiotics. 2024 Mar 28
- 4 citationsUnderstanding Treatment Response in Individual Profiles of Men with Prostatic Enlargement at Risk of Progression.Stavros Gravas, Juan Manuel Palacios-Moreno, Douglas Thompson, Federico Concas, Piotr J Kamola, Claus G Roehrborn, Matthias Oelke, Michael W Kattan, Marcio Augusto Ave...> ;European Urology Focus. 2023 Jan 1
- 7 citationsModel-based meta-analysis of the time to first acute urinary retention or benign prostatic hyperplasia-related surgery in patients with moderate or severe symptomsSalvatore D'Agate, Chandrashekhar Chavan, Michael J. Manyak, Juan Manuel Palacios-Moreno, Matthias Oelke, Martin C. Michel, Claus G. Roehrborn, Oscar Della Pasqua> ;British Journal of Clinical Pharmacology. 2021 Jul 1
- Join now to see all
Press Mentions
- Impact of Early vs. Delayed Initiation of dutasteride/tamsulosin Combination Therapy on the Risk of Acute Urinary Retention or BPH-Related Surgery in LUTS/BPH Patients with Moderate-to-Severe Symptoms at Risk of Disease ProgressionDecember 18th, 2020
Professional Memberships
- Member
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence: